

VolitionRx

13:30 25 Oct 2019

VolitionRx's veterinary subsidiary wins 12.5% equity stake from Texas A&M

VolitionRx Limited (NYSEAMERICAN:VNRX) announced Friday that Texas A&M University has taken roughly a 12.5% equity stake in its subsidiary Volition Veterinary Diagnostics Development LLC.

In a statement, Belgium-based company said that Texas A&M also will provide its expertise and conduct specified research and development activities.

Under the agreement, Volition (through its subsidiaries) said it will provide certain parts of its intellectual property associated with its proprietary Nu.Q platform and assays as well as an aggregate of \$400,000 to the school and affiliated entities towards the collaboration.

READ: VolitionRx hits milestone in Nu.Q Capture blood-based cancer-detection technology

Volition's NuQ platform looks for molecular signatures of cancer by focusing on the nucleosomes - a section of DNA wrapped around a core of proteins - in the blood. As cancer cells multiply, they are modified in a way that distinguishes them from healthy cells and the traits of the malignant disease appear on the nucleosomes, which are analyzed by the platform.

The company and the university together have been studying a version of its blood-based tests for animals called Nu.Q Vet after discovering that nucleosomes in the blood can also be detected in dogs.

"The Texas A&M College of Veterinary Medicine & Biomedical Sciences is excited to be working with Volition to develop tests for the early detection of cancer and other diseases in animals," said Dr Eleanor Green, the Carl B King Dean of Veterinary Medicine at Texas A&M.

"The research and clinical trials conducted by CVM's veterinary oncologists work on the cutting-edge of medicine and have benefitted both humans and animals. The goal of this project with Volition is to provide all veterinarians with simple, affordable, routine blood tests that can help identify disease early and improve the lives of both animals and the people who love them."

CEO Cameron Reynolds noted he "enjoyed the hospitality of Texas A&M and (is) very impressed with the caliber of personnel and fantastic facilities in the veterinary school."

The company's stock recently traded up 3.7% to \$5.89 a share in New York.

Contact the author: patrick@proactiveinvestors.com

Follow him on Twitter @PatrickMGraham

Price: 3.33

Market Cap: \$137.21 m

1 Year Share Price Graph



February 2019 August 2019 February 2020

Share Information

Code: VNRX

Listing: NYSEMKT

52 week	High	Low
	6.83	2.65

Sector: Pharma & Biotech

Website: volitionrx.com

Company Synopsis:

Volition is a multi-national life sciences company developing simple, easy to use blood-based cancer tests to accurately diagnose a range of cancers. The tests are based on the science of Nucleosomics®, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid -- an indication that disease is present. .

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of VolitionRx named herein, including the promotion by the Company of VolitionRx in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).